Noteworth Secures $5 Million in Funding

July 15, 2020

Noteworth, a first-of-its-kind Digital Healthcare platform for modernizing Digital Medicine delivery operations, announced a $5 million oversubscribed seed funding round led by Laconia Capital Group with participation from Draper Associates, Frontier Ventures, Techstars Ventures, Wavemaker360, Springtide Capital and others.

Noteworth states the funding will be used to expand operations of their digital medical technology and make strategic hires necessary to meet the growing demand from healthcare providers and patients.

With this new investment, the company will continue to build upon the delivery of Noteworth’s first-of-its-kind Digital Healthcare platform. The platform provides a number of beneficial capabilities including expanded access to care in order to eliminate the barriers to care by putting health services into the patient’s hands. One of the main goals for the company is working to extend patient engagement by providing clinicians with the tools to communicate directly with patients through video, chat, and push notifications. The Noteworth platform works to help reduce costs by decreasing readmissions and the use of high-cost services with timely interventions. In addition, Noteworth will help clinicians obtain new reimbursements to generate additional income for new streams of revenue.

“The positive response and support of our strategic investors reflect a shared belief that digital medicine is the future of healthcare delivery,” said Justin Williams, Co-founder, and CEO of Noteworth. “With this new round of funding, Noteworth will continue to establish our ability to quickly and efficiently help healthcare providers launch our digital medicine technology platform offering to better serve their patient populations remotely.”

“Noteworth is a rising star in the field of digital medicine,” said David Arcara, Managing Partner of Laconia Capital Group. “Their ability to provide unprecedented healthcare data collection, assessment and proactive intervention across all current digital healthcare information silos, consistent with our investment thesis focused on digital workflow transformation, is what prompted our investment in this critical technology that is modernizing healthcare delivery. Laconia invests in companies that pioneer the digital transformation from legacy software and manual workflow processes into 21st century cloud-based platforms.”

“At Draper Associates, we are looking for companies that can become fundamental to an industry,” said Tim Draper, Founder and Managing Partner of Draper Associates. “Noteworth is an easy to use system that monitors the patient’s progress, improves profitability for the caregiver and derives insightful data for health care generally. We expect every doctor and every patient to be a part of this easy-to-use communications tool.”

SourceNoteworth
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy